This therapeutic concept targets excitotoxic stress — a common terminal pathway in neurodegenerative diseases — through selective transcriptional upregulation of EAAT2 (also known as GLT-1 or SLC1A2) in astrocytes. EAAT2 is the dominant glutamate transporter in the brain, responsible for clearing ~90% of synaptic glutamate. When EAAT2 expression or function declines, glutamate accumulates in the synaptic cleft, leading to chronic NMDA/AMPA receptor overactivation, calcium dysregulation, and ultimately neuronal death.[1][2]
The EAAT2 transcription reboot strategy combines:
This approach is distinct from:
EAAT2 (Excitatory Amino Acid Transporter 2) is encoded by the SLC1A2 gene and is expressed predominantly in astrocytes, with lower expression in neurons. Each EAAT2 transporter can clear ~10,000 glutamate molecules per second, making it the primary mechanism for terminating glutamatergic transmission and preventing excitotoxicity.[3]
Key facts about EAAT2:
Multiple studies document EAAT2 dysfunction across neurodegenerative diseases:
| Disease | EAAT2 Abnormality | Evidence |
|---|---|---|
| ALS | 70-90% reduction in motor cortex | Rothstein et al., 1995 [1:1] |
| AD | Reduced expression in hippocampus | Masliah et al., 1996 [4] |
| PD | Decreased in substantia nigra | Clinchot et al., 1994 [5] |
| HD | Impaired astrocytic glutamate uptake | Faideau et al., 2010 [6] |
The consistent pattern: EAAT2 loss is not a cause of disease but amplifies whatever primary pathology exists, making it a high-leverage therapeutic target regardless of upstream trigger.
Previous EAAT2-targeted approaches focused on:
The limitation: these approaches either:
The transcription reboot approach seeks sustained, astrocyte-specific expression through:
In AD, excitotoxicity contributes to cognitive decline through:
EAAT2 reboot addresses:
PD involves:
EAAT2 reboot could:
ALS shows the most dramatic EAAT2 loss:
EAAT2 reboot offers:
Cerebrovascular disease and vascular contributions to dementia (VaD/mixed dementia) involve:
EAAT2 reboot could protect against vascular-mediated excitotoxicity.
Novel small molecules (in development):
Gene therapy:
Since inflammation suppresses EAAT2 expression, combining with anti-inflammatory approaches:
Astrocyte glutamate clearance is ATP-dependent:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7 | EAAT2-targeting is established; transcriptional reboot + combination is novel |
| Mechanistic Rationale | 8 | Strong evidence for EAAT2 loss in AD/PD/ALS; transcriptional approach addresses root cause |
| Addresses Root Cause | 8 | Restores primary glutamate clearance mechanism, not just symptom management |
| Delivery Feasibility | 6 | Astrocyte-targeting remains challenging; gene therapy faces BBB/delivery hurdles |
| Safety Plausibility | 7 | Excess glutamate clearance is unlikely harmful; monitor for hyperexcitability |
| Combinability | 9 | Highly synergistic with anti-inflammatory, metabolic, and neuroprotective approaches |
| Biomarker Availability | 6 | EAAT2 expression in CSF/ blood; glutamate levels; but specificity limited |
| De-risking Path | 7 | Ceftriaxone precedent; clear regulatory pathway for ALS |
| Multi-disease Potential | 8 | AD, PD, ALS, HD, VCI — excitotoxicity is universal |
| Patient Impact | 7 | Could slow progression in broad population |
| Total | 76 |
| Biomarker | Readout | Source |
|---|---|---|
| EAAT2 mRNA | Transcriptional activation | Blood PBMCs, CSF cells |
| EAAT2 protein | Expression level | CSF, brain imaging (PET ligand development) |
| Glutamate clearance | Functional readout | MRS glutamate dynamics |
| CSF glutamate | Substrate level | CSF |
| Neurofilament light | Neuronal injury | Blood, CSF |
| Inflammatory markers | IL-6, TNF-α | Blood |
| Milestone | Timeline | Estimated Cost |
|---|---|---|
| High-throughput screen for EAAT2 transcriptional activators | Months 1-6 | $500K |
| Lead optimization | Months 7-12 | $750K |
| Subtotal | $1.25M |
| Milestone | Timeline | Estimated Cost |
|---|---|---|
| GLP toxicology (rodent) | Months 1-6 | $800K |
| GLP toxicology (NHP) | Months 7-14 | $1.2M |
| IND-enabling studies | Months 12-18 | $600K |
| Subtotal | $2.6M |
| Milestone | Timeline | Estimated Cost |
|---|---|---|
| Phase 1a (healthy volunteers) | Months 1-12 | $3M |
| Phase 1b (patients) | Months 10-24 | $4M |
| Phase 2 | Months 18-36 | $8M |
| Subtotal | $15M |
Total Estimated Cost: ~$19M to Phase 2 completion
Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in ALS. Annals of Neurology. 1995. ↩︎ ↩︎
Fontana AC. Current approaches to enhance glutamate transporter expression and function. Neurochemistry International. 2015. ↩︎
Danbolt NC. Glutamate uptake. Progress in Neurobiology. 2001. ↩︎
Masliah E, Alford M, Mallory M, et al. Glutamate transporter alterations in Alzheimer disease. Neuroscience Letters. 1996. ↩︎
Clinchot DM, Greig NH, Rapoport SI. Naltrexone and fluoxetine modulate glial cell line-derived neurotrophic factor in an in vitro model of Parkinson's disease. Brain Research. 1994. ↩︎
Faideau M, Kim J, Cormier K, et al. Dysregulation of glutamate transporter expression in Huntington's disease. Brain Research. 2010. ↩︎
NCT00349674. Phase 3 Study of Ceftriaxone in Subjects With ALS. ↩︎
Bellingham MC. A review of the pharmacological mechanisms of action of riluzole in ALS. Journal of Neurology. 2012. ↩︎
Texido LH, Egea G, Saura CA. Glutamate excitotoxicity in Alzheimer's disease. Journal of Alzheimer's Disease. 2011. ↩︎